Letter to the Editor regarding Hydroxyurea reduces the levels of the fetal globin gene repressors ZBTB7A/LRF and BCL11A in erythroid cells in vitro
Author:
Open Access
- 7 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 1 (1)
Abstract
Hydroxyurea is beneficial to patients with sickle cell disease because it increases fetal hemoglobin (HbF), which reduces red blood cell sickling. The mechanism by which hydroxyurea increases fetal hemoglobin is not well established. Martyn et al. show that hydroxyurea treatment of in vitro-differentiated erythroid precursors results in reduced expression of BCL11A and ZBTB7A/LRF, two transcription factors that are well-established repressors of the gamma-globin gene. Interestingly, hydroxyurea also reduces the amount of GATA1 in the cells, and since GATA1 is a positive regulator of the BCL11A and ZBTB7A/LRF genes, this suggests that GATA1 may mediate the effects of hydroxyurea. The work provides hints about the mechanism of action of hydroxyurea, but also leaves open questions about its complex role in increasing fetal hemoglobin.Keywords
This publication has 6 references indexed in Scilit:
- Hydroxyurea reduces the levels of the fetal globin gene repressors ZBTB7A/LRF and BCL11A in erythroid cells in vitroJournal of Sickle Cell Disease, 2024
- Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobinScience, 2016
- Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11AScience, 2008
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- The erythroid-specific transcription factor eryf1: A new finger proteinCell, 1989
- Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cellsNature, 1989